Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® from Sanofi US

Cosette Pharmaceuticals, a specialty pharmaceutical company based in the United States, has successfully acquired the rights to Ambien® and Ambien CR® from Sanofi US for the US market. This strategic acquisition aims to ensure the continued supply of these medications to patients who rely on them.

Apurva Saraf, President and CEO of Cosette, expressed enthusiasm over the acquisition, stating that the addition of Ambien to their product lineup bolsters the company's portfolio and underscores its dedication to providing high-quality pharmaceuticals to patients worldwide. The acquisition is also seen as a testament to Cosette's proficiency in executing complex business deals and integrating diverse pharmaceutical products into its operations.

According to market data from IQVIA®, the US annual sales for Ambien® and Ambien CR® amounted to $39 million for the 12 months ending in April 2024. This substantial market presence highlights the critical nature of ensuring that the supply of these medications remains uninterrupted.

Cosette has a proven track record of acquiring or carving out products from global pharma companies, including those in Japan, Europe, and the USA. The company employs a strategic approach that leverages its deep industry expertise to ensure seamless transitions during product divestitures and acquisitions. This strategy has been instrumental in maintaining uninterrupted access to essential medicines for millions of patients.

Cosette Pharmaceuticals is known for its expertise in manufacturing a variety of complex dosage forms, such as topical creams, ointments, oral liquids/solutions, and suppositories. The company’s corporate and manufacturing facilities are located in New Jersey and North Carolina, and it is supported by a team of over 300 employees across various functional areas. The company is backed by Avista Capital Partners, a private equity firm focused on healthcare investments.

In summary, the acquisition of Ambien® and Ambien CR® by Cosette Pharmaceuticals is a significant move that underscores the company's commitment to expanding its portfolio and ensuring the availability of critical medications. This acquisition not only strengthens Cosette's market position but also highlights its capability in managing complex business transactions and integrating new products seamlessly.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!